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ABSTRACT
Recent clinical studies indicate that adoptive T-cell therapy and especially chimeric antigen receptor (CAR)
T-cell therapy is a very potent and potentially curative treatment for B-lineage hematologic malignancies.
Currently, autologous peripheral blood T cells are used for adoptive T-cell therapy. Adoptive T cells
derived from healthy allogeneic donors may have several advantages; however, the expected occurrence
of graft versus host disease (GvHD) as a consequence of the diverse allogeneic T-cell receptor (TCR)
repertoire expressed by these cells compromises this approach. Here, we generated T cells from cord
blood hematopoietic progenitor cells (HPCs) that were transduced to express an antigen receptor (AR):
either a CAR or a TCR with or without built-in CD28 co-stimulatory domains. These AR-transgenic HPCs
were culture-expanded on an OP9-DL1 feeder layer and subsequently differentiated to CD5CCD7C T-
lineage precursors, to CD4C CD8C double positive cells and ﬁnally to mature ARC T cells. The ARC T cells
were largely naive CD45RACCD62LC T cells. These T cells had mostly germline TCRa and TCRb loci and
therefore lacked surface-expressed CD3/TCRab complexes. The CD3¡ AR-transgenic cells were mono-
speciﬁc, functional T cells as they displayed speciﬁc cytotoxic activity. Cytokine production, including IL-2,
was prominent in those cells bearing ARs with built-in CD28 domains. Data sustain the concept that cord
blood HPC derived, in vitro generated allogeneic CD3¡ ARC T cells can be used to more effectively
eliminate malignant cells, while at the same time limiting the occurrence of GvHD.
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Introduction
Adoptive transfer of gene-modiﬁed T cells expressing either
chimeric antigen receptors (CARs) or tumor-speciﬁc T-cell
receptors (TCRs) constitutes a novel and, under certain condi-
tions, a highly effective strategy to treat malignancies. Clinical
trials involving CAR T-cell therapy have demonstrated impres-
sive clinical responses in CD19C acute lymphoblastic leukemia
with reported complete remission rate of about 90%.1-3
CARs are artiﬁcial modular proteins consisting of a single
chain variable fragment for antigen recognition, a spacer, a
transmembrane region and one or more intracellular functional
sequences derived from CD3z and co-stimulatory molecules
such as CD137 or CD28.4 First-generation CARs carry only the
CD3z intracellular sequence. First-generation CAR T cells how-
ever do not display potent antitumoral responses in vivo. Sec-
ond-generation CAR T cells have besides CD3z also a co-
stimulatory domain that prevents the development of anergy
and increases interleukin-2 (IL-2) production upon antigenic
stimulation.5 All clinical trials that reported high rates of clini-
cal responses involved second-generation CAR T cells with
either CD28 or CD137 as co-stimulation.
TCR transgenic T cells directed to tumor antigens such as NY-
ESO-1 and MART1 have also entered clinical trial to study their
efﬁcacy in melanoma, sarcoma and multiple myeloma.6,7 Clinical
TCR gene therapy studies may be challenged by (1) low afﬁnity of
the receptor (directed towards autoantigens), (2) interference of
the endogenous TCR with the expression of the transgenic TCR
either by cross-pairing of the TCRa and TCRb chains or by com-
petition for CD3,8-13 (3) the generation of graft versus host disease
(GvHD)13 and/or (4) the lack of co-stimulation.14 Several strategies
have been reported to address these challenges such as increasing
afﬁnity of the TCR, preventing cross-pairing by introducing cyste-
ine residues in the transgenic TCR chains, by gene editing the
endogenous TCR loci or, similar to CARs, by inclusion of CD3z
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and CD28 sequences in the TCRa and TCRb construct (TCR with
built-in co-stimulation).8,9,15-20
In some malignancies, CAR T cells seem to be less potent to
eradicate the tumor than in others. For instance, CD19 CAR T
cells seem to be less efﬁcient in non-Hodgkin lymphoma than
in acute lymphoblastic leukemia.21 In addition, the effectiveness
seems to be dependent on the intensity of the conditioning regi-
men, suggesting that concomitant chemotherapy acts synergisti-
cally due to the added antitumoral effect and/or due to the
immune suppressive effect that inhibits anti-CAR T-cell
immune responses by the patient.1,2,22 These data suggest that
for some malignancies, CAR T-cell therapy should be combined
with other therapeutic regimens to increase cure rate. One pos-
sibility is to combine antigen receptor (AR) T-cell therapy with
allogeneic stem cell transplantation and/or chemotherapy.
Directing allogeneic T cell toward deﬁned cancer antigens, while
at the same time avoiding the toxicity of these T lymphocytes
caused by alloreactivity of the polyclonal TCR repertoire, may
provide a very potent and safe therapy in combination with che-
motherapy. For these reasons, it could be beneﬁcial to generate
ARC T cells from allogeneic sources such as banked cord blood
or from adult allogeneic donors.23-25 To prevent GvHD, expres-
sion of the endogenous TCRs by the peripheral blood T cells
should be suppressed to generate mono-speciﬁc CAR or TCR-
transgenic T cells. Various methods have been described to
accomplish this, mostly based on the targeting of the Ca of the
TCR locus either by gene editing or siRNAs.15,26
We previously reported that mono-speciﬁc TCR-transgenic
cells lacking endogenous rearrangements can be generated
from cord blood hematopoietic progenitor cells (HPCs).27 This
method is based on allelic exclusion, a phenomenon that occurs
physiologically in the thymus and that ensures that each T cell
successfully rearranges only a single TCRb locus. Because of
allelic exclusion, T cells generated from TCR-transgenic HPCs
do not rearrange endogenous TCR loci and T cells that are gen-
erated are mono-speciﬁc and express only the transgenic TCR.
This strategy involves transduction of HPCs to express a
tumor-speciﬁc TCR and subsequent differentiation of the
HPCs to T cells on OP9 feeder cells in the presence of cytokines
and Notch stimulation.
Here, we have investigated whether CARs and TCRs with or
without built-in CD28 co-stimulatory domain could inhibit
rearrangements of endogenous TCR loci while at the same time
allow the generation of functional transgenic ARC, tumor-spe-
ciﬁc T cells. In addition, we assessed whether cells expressing
ARs with built-in CD28 co-stimulation acquired more potent
T-cell functional capacity. We observed that very potent func-
tional T cells can be generated using this strategy and that these
cells express the transgenic CAR or TCR in the virtual absence
of rearranged endogenous TCR loci. These cells are therefore
assumed to be devoid of alloreactivity.
Results
Antigen receptor transgenic CD34C HPCs differentiate to
mature T cells on OP9-DL1 feeder cells
Human T-lineage committed CD34C HPCs either isolated
directly from thymus or generated in vitro from cord blood
CD34C cells were transduced to express a “second-generation”
carcino-embryonic antigen (CEA)-speciﬁc CAR carrying an
intracellular CD3 z-chain signaling sequence and the trans-
membrane and co-stimulatory CD28 intracellular signaling
sequence (CAR:28z) (Fig. S1). Twenty to sixty percent of the
cells expressed the CAR and the co-transduced GFP after trans-
duction. Transduced GFPC and untransduced GFP¡ cells were
subsequently cultured together on OP9-DL1 feeder cells for
25 d in the presence of growth factors to obtain CARC T cells
(Fig. 1A). Compared to untransduced cells, the percentages of
immature CD4C (7.2% vs 13.6%) and CD4CCD8C double posi-
tive (DP) (51.9% vs 64.2%) cells were consistently reduced in
the GFPC CAR transgenic population due to a prominent pop-
ulation of mature CD27C CD1a¡ cells, which were virtually all
double negative (DN) or CD8C (not shown), in the CAR trans-
genic cells whereas only few mature CD27CCD1a¡ cells were
present in untransduced cultures (45.3% vs 2.6%).
We have shown previously that, in untransduced OP9-
DL1 cultures, mature T cells are mainly TCRgdC cells.28 In
addition, we have shown that in cultures initiated with HPCs
transduced to express a TCRab, mature CD27CCD1a¡ T
cells are virtually absent, but addition of the agonist peptide
in the presence of the restricting HLA antigen induces matu-
ration.27 Here, antigen-dependent maturation is unlikely as
CEA expression analysis on these cultures with qPCR was
consistently negative (data not shown). Subsequently, we
investigated whether CD28 co-stimulatory signals may be
inducing terminal maturation in the absence of ligand. Cul-
tures transgenic for a “ﬁrst-generation” CAR containing only
the transmembrane and intracellular CD3z-chain signaling
sequence (further referred as CAR:z) and cultures transgenic
for the second-generation CAR containing the transmem-
brane and intracellular CD28 signaling sequence as well as
the intracellular CD3z-chain signaling sequence (CAR:28z),
both speciﬁc for CEA, were compared side by side (Fig. 1B).
The percentage of DPs of the GFPC CAR transgenic cells
was higher in the CAR:z transduced cells compared to the
CAR:28z transduced cells (45.2% vs 33.5% at day 14, 63.5%
vs 36.8% at day 25). At the same time, the level of antigen-
independent maturation as evidenced by the presence of
mature CD27CCD1a¡ cells was lower in the CAR:z trans-
genic cells compared to the CAR:28z transgenic cultures
(2.1% vs 11.3% at day 14, 10.3% vs 36.0% at day 25). These
differences were not caused by a co-stimulator-induced
acceleration of T-cell differentiation as this phenomenon
was observed in early (day 14) as well as in late (day 25) cul-
tures. We hypothesized that the number of CAR molecules
per cell may impact the signaling strength. Accordingly, the
CAR:z was expressed to a lower degree than the CAR:28z,
while the transduced cells expressed the same GFP levels
(Fig. 1C). To exclude that differences in antigen-independent
maturation of the different transgenic cells was caused by
differential expression levels of the CAR rather than the co-
stimulatory properties and/or the transmembrane domain of
the CAR, we stained the different CARs directly with anti-
human IgG1 antibody, which binds to the extracellular
spacer of the CAR, and compared percentages of DPs and of
mature cells for both transgenic cells. For cells with the same
expression levels of the AR, a decreased percentage of DPs
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(48.6% vs 60.8% and 28.9% vs 60.0%) and an increased per-
centage of antigen-independent maturation (32.4% vs 8.6%
and 37.5% vs 16.6%) were noted in CAR:28zC cells vs
CAR:zC cells. AR expression levels also contributed, with
high AR-expressing cells maturing at higher frequencies
than low AR-expressing cells (16.6% vs 8.6% and 37.5% vs
32.4%). We conclude that phenotypically mature T cells are
generated from CAR transgenic cells in a ligand-independent
manner and that the efﬁciency of maturation is dependent
on the levels of AR expression and on the presence of co-
stimulatory domain and/or the nature of the transmembrane
domain in the AR.
In addition, the dimerized CD3z intracellular domain of the
ﬁrst-generation CAR:z itself seems to induce a prominent
Figure 1. Differentiation of T-lineage committed CD34 cells after transduction with various antigen receptor constructs. Thymus-derived T-lineage CD34C precursor cells
were transduced to express a transgenic AR and subsequently cultured on OP9-DL1 feeder cells to induce terminal T cell maturation. (A) Flow cytometric analysis of
transduced GFPC and untransduced GFP¡ cells 25 d after transduction of the cells to express the CAR:28z speciﬁc for CEA and subsequent culture on OP9-DL1 feeder
cells. (B) T-lineage CD34C precursor cells transduced to express the CAR:z or the CAR:28z. GFPC cells are shown after 14 d and 25 d of culture (N D 5). (C) T-lineage
CD34C precursor cells transduced to express the CAR:z or the CAR:28z 25 d after the initiation of culture on OP9-DL1 feeder cells. The transgenic CAR was recorded using
an anti-human IgG1 antibody. The percentages of CD4C CD8b co-expressing cells and of mature CD27CCD1a¡ cells were determined within a gate for cells with low CAR
expression and a gate for cells with high CAR expression for CAR:z and CAR:28z transgenic cultures (N D 3).(D) T-lineage CD34C precursor cells transduced to express the
HLA-A2 restricted, gp100 speciﬁc wtTCR, TCR:z or the TCR:28z. Vb14bC cells are shown after 20 d of culture on OP9-DL1 feeder cells (N D 5), and (E) after an additional
7 d culture in the presence of the speciﬁc peptide (N D 2).
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antigen-independent maturation (Fig. 1D and E). To further
substantiate this, we generated modular receptors from a
cloned TCR similar to CARs. Both the a and the b chains of a
wildtype (wt) HLA-A2 restricted TCR speciﬁc for gp100 were
linked with the intracellular domain of the CD3z only (TCR:z)
or in addition to the CD28 co-stimulatory domain (TCR:28z)
(Fig. S1). HPCs transgenic for the wtTCR, for the TCR:z and
the TCR:28z were identiﬁed by positive staining for Vb
(Fig. 1D). wtTCR transgenic cells generated only a low percent-
age of mature T cells in the absence of the TCR ligand, as
expected (1.1%). In contrast to ﬁrst-generation CARs, we did
not observe increased ligand-independent maturation of the
TCR:z transgenic cultures (1.4%) compared to wtTCR. How-
ever, when a co-stimulatory CD28 domain was included in the
TCR, we did observe an increased efﬁciency of ligand-indepen-
dent maturation (6.0%). As previously described,27 addition of
the TCR cognate peptide further increased maturation of the
wtTCR transgenic cells to mature CD27CCD1a¡ T cells
(28.0%). This was also the case for the TCR:z and TCR:z:28
transgenic cells (62.6% and 80.9%, respectively) (Fig. 1E). In
conclusion, wtTCR and TCR with incorporated CD3z required
speciﬁc ligand to drive maturation of the T cells, whereas TCR
with incorporated CD28 transmembrane and co-stimulatory
domain induced antigen-independent maturation of T-cell pre-
cursors which can be further enhanced by addition of ligand.
Since DP cells are highly proliferative cells in culture, we
asked whether premature ligand-independent maturation of
the precursor cells impacts cell expansion in OP9-DL1 cul-
tures of cells transgenic for ARs with built-in CD28
sequence. In Fig. 2A, expansion after CAR transduction is
presented. Consistent with the lower levels of DP cells
observed in CAR:28z transgenic cells, total expansion of
these cells was lower than that of ﬁrst-generation CAR:z
transgenic cells (670- vs 1361-fold increase for CAR:28z
and CAR:z AR-transgenic cultures, respectively, on day 19).
Although the total number of cells and the number of DPs
that were obtained for TCR:28z-transgenic cells were signiﬁ-
cantly lower, the number of CD27CCD1a¡ mature T cells
obtained from these cultures tended to be higher mainly
due to late generation and/or expansion of mature T cells
(388- vs 134-fold CAR:28z and CAR:z AR-transgenic cul-
tures, respectively, on day 25). Similar expansion rates were
observed for the TCR constructs (Fig. 2B). T-lineage com-
mitted HPCs transgenic for wtTCR expanded early together
with the generation of DP cells, but a few mature cells are
generated without agonist stimulation. TCR:z transgenic
cells generated comparable cell numbers but more
CD27CCD1a¡ mature T cells were generated. Cultures
transgenic for TCR:28z displayed reduced early proliferation
due to defective DP generation; however, at later stage
more CD27CCD1a¡ mature T cells were generated, suggest-
ing that co-stimulatory signaling induces longer survival or
proliferation of mature T cells in vitro. In all cases, total
cell expansion starting from fresh CD34C HPCs is substan-
tial (Fig. 2C). After initial culture on OP9-DL1 for 10–14 d,
the T-lineage committed cells are transduced and further
cultured on OP9-DL1 for additional 28–35 d. Total expan-
sion rates were 1.56£104 times for ﬁrst-generation CAR:z
transgenic cells compared to 5.23£103 for cultures with
second-generation CAR:28z. In conclusion, AR-transgenic
HPCs from cord blood can be expanded more than 1000-
fold and differentiated in OP9-DL1 cultures to mature cells.
Unlike wtTCR transgenic HPCs, AR transgenic cells with
build-in CD28 co-stimulator sequence did not require anti-
gen for expansion.
AR-transgenic CD34C HPCs generate ARC T cells that lack
CD3 membrane expression
Since CARs do not require CD3 for membrane expression,
we checked whether the cells generated in these cultures had
TCR/CD3 complexes expressed on the membrane. In Fig. 3A,
it is shown that >7% of the untransduced GFP¡ cells express
CD3 in combination with either a TCRab or a TCRgd recep-
tor. In contrast, the GFPC CAR transgenic cells in the same
cultures are largely CD3 negative, despite the presence of a
higher percentage of mature CD27C CD1a¡ cells (Fig. 1).
This was the case for both CAR:z and CAR:28z transgenic
cultures. A similar phenomenon was observed in TCR-trans-
genic cultures (Fig. 3B). wtTCR transgenic cells expressed
CD3 as well as the transgenic TCR, as evidenced by the
Vb14 expression. In contrast, Vb14-expressing TCR:z and
TCR:28z transgenic cells expressed the AR in the absence of
CD3 membrane expression16,20. These transgenic cells
expressed no CD3. A small population of Vb14C cells
expressed CD3, but these are most likely untransduced cells
that have rearranged the endogenous TCR at the Vb14 gene
segment. To exclude that the CD3/TCR complex was not
expressed on the membrane of CAR-transgenic T cells due to
the absence of CD3 protein expression, we performed cyto-
plasmic CD3e staining. Fig. 3C shows that cCD3 was present
at high levels in the cytoplasm, but not on the cell surface
(sCD3), which is likely due to the absence of rearranged
endogenous TCRs rather than due to the non-T-cell nature
of the cells. Cytoplasmic expression of CD3 suggests that the
CARC, TCR/CD3¡ cells are bona ﬁde T cells. However, natu-
ral killer (NK) cells generated from cord blood on OP9-DL1
feeder cells may also express cytoplasmic CD3.29 We therefore
analyzed the mature CARC cells for other T and NK-lineage
markers. The CAR transgenic cells were positive for CD5,
CD7 and CD2 (Fig. 3D). The combination of these three
markers is exclusively expressed by T cells, whereas NK cells
are consistently CD5¡. While NK cells are deﬁned as CD3¡
CD56C cells, the CARC cells generated in vitro were to a
large degree negative for the NK cell marker CD56. Only a
minor population of the cells was CD56C, a marker that is
also present on activated T cells. NKG2D, a marker for both
NK cells and mature CD8C single positive T cells, was
expressed on these cells.
To further substantiate the T-cell nature of the CARC CD3¡
cells, we initiated an OP9-DL1 culture with a pure population
(>99%) of CD34C cord blood cells (Fig. 3E). Thirteen days later,
the T-cell lineage committed CD5CCD7C cells were again sorted
to homogeneity (>99% purity), transduced and put back in cul-
ture to obtain mature T cells. Another 8 d later, GFPC CARC
DP cells as well as GFPCCARC CD27CCD1a¡ mature cells were
generated from these cultures, indicating that the CARC mature
cells were efﬁciently generated from CD5CCD7C T-lineage
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precursors and therefore are T lineage cells despite the absence
of membrane CD3 expression. We therefore conclude that the
CARCCD3¡ cells represent mature T cells.
The CARC mature T cells were heterogeneous with respect
to CD45RA/CD45RO expression (Fig. 3D). However, most cul-
tures generated a large population of CD62LC CD45RAC
CD45RO¡ cells, indicating that the generated T cells have a
naive T-cell phenotype (Fig. 3F). As expected, the CAR T-cell
populations did not contain CD4C T cells. Most CARC cells
were either double negative (DN) or expressed CD8a and
CD8b, similar to the reported phenotype of TCRab transgenic
T cells generated on OP9-DL1 feeder cells.
CD34C HPC derived transgenic ARC T cells lack
endogenous TCRa and TCRb rearrangements
We previously reported that transgenic expression of a
wtTCRab in HPCs completely suppresses rearrangements
of the endogenous TCRb locus and that agonist selection
by TCR stimulation suppresses rearrangements of the
endogenous TCRa locus, resulting in mature T cells that
express only the transgenic TCR.27. In line with this, we
showed evidence in the previous section that the CAR:z,
CAR:28z, TCR:z and TCR:28z expressing cells were CD3
negative, suggesting the absence of endogenous
Figure 2. Expansion of T-lineage committed and fresh CD34C HPC-derived transgenic ARC T cells. Expansion and differentiation of the various AR-transgenic cell popula-
tions. (A) Progeny of one CD34C cell obtained from thymus after transduction with the CAR:z or CAR:28z speciﬁc for CEA. Error bars represent SD, N D 3. (B) Progeny of
one CD34C cell obtained from thymus after transduction with the gp100-speciﬁc, HLA-A2 restricted wtTCR, the TCR:z or the TCR:28z construct with the same speciﬁcity.
Error bars represent SD, N D 5. (C) Progeny of fresh CD34C cord blood cells expanded and differentiated on OP9DL1 feeder cells for 13 d to CD5CCD7C T-lineage
restricted precursors and subsequent transduction to express the CAR:z or CAR:28z speciﬁc for CEA. Error bars represent SD, N D 3.
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rearrangements of the TCR loci. To further substantiate the
absence of endogenous rearrangements, we measured
mRNA levels coding for the different components of the
CD3/TCR complex in the (TCR-negative) CAR transgenic
HPC-derived cell lines. Transcripts encoding CD3g, CD3d,
CD3e and CD3z were detected, whereas TCRa and TCRb
transcripts were selectively lacking in the HPC-derived cell
lines (Fig. 4A). Next, we analyzed whether a second
transduction to express a transgenic (CMV-speciﬁc)
wtTCRa or a wtTCRb chain or both could induce mem-
brane expression of the CD3 complex in TCR:z and
TCR:28z transgenic HPC-derived cell lines. As expected,
when both wtTCR chains were introduced, membrane CD3
expression was observed in both cell lines, indicating that
all components required for TCR expression were present.
However, introduction of only the TCRa chain failed to
Figure 3. Phenotype and endogenous TCR expression of CD34C HPC-derived transgenic ARC T cells. Flow cytometric analysis of the AR-transgenic T cells. (A) CAR-trans-
genic GFPC cells of cultures transduced to express either the CAR:z or the CAR:28z were analyzed on day 26 of OP9-DL1 culture for CD3 and TCRab expression. As a con-
trol, GFP¡ cells are shown from the OP9-DL1 culture transduced to express the CAR:z (N D 5). (B) Dot plots show CD3 expression of cells from the OP9-DL1 cultures
transgenic for the wtTCR, TCR:z and TCR:28z. Vb14 staining is used to mark transgene expression, as no GFP is expressed by the transgenic cells (N D 5). (C) Surface and
cytoplasmic staining for CD3 of in vitro generated mature T cells that were expanded for one cycle on feeder cells in the presence of cytokines. (D) Expression of various
membrane markers by the CD27CCD1a¡mature T cells at the end of OP9-DL1 culture (46 d) (ND 2). (E) Day 0: fresh cord blood after MACS CD34 enrichment sorted using
the sorting window shown. Day 13: cord blood cells cultured on OP9-DL1 were sorted for CD5 CD7 double positive cells, using the indicated sorting window. The cells
were then transduced to express CAR:28z and further differentiated on OP9-DL1 feeder layer. Day 21: analysis of the transgenic GFPC cultured cells for DP cells and
CD27CCD1a¡ mature cells. (F) Flow cytometric analysis of GFPC CAR:28z-transgenic cultures, gated on GFPC CD27C CD1a¡ mature ARC cells (N D 2).
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Figure 4. TCRa and TCRb rearrangements in CD34C HPC derived transgenic ARC T cells. (A) Expression of the various components of the CD3/TCRab complex at the
mRNA level. RT-PCR was performed on the JY B cell line as negative control, on a CAR:28z transgenic PBMC-derived T cell line (PBMC) as a positive control and on CAR
transgenic HPC-derived cell lines of OP9 cultures transduced to express either the CAR:z (CAR:z) or the CAR:28z (CAR:28z). (B) TCR:z and TCR:28z transgenic CD3-negative
HPC-derived T-cell lines were transduced to express the TCRa chain of a CMV-speciﬁc TCR and GFP as marker, the TCRb chain with truncated NGFR as marker or with
both TCR chains. Three days later, cells were gated for GFPC, NGFRC or double positive cells and the CD3/TCRab expression was measured. Note that the TCRab anti-
body does not bind CD3-negative TCR:z nor TCR:28z complex although it binds to wtTCR/CD3 complexes. Percentage CD3/TCR positive cells is indicated in the upper
right quadrant. (C) Histograms of read counts per CDR3 nucleotide length. CDR3a and CDR3b histograms are shown for wtTCR, TCR:z, TCR:28z, CAR:z and CAR:28z trans-
genic HPC-derived cell lines and as a control CAR:28z transgenic PBMC-derived T-cell line. All samples were spiked with Jurkat T cell line mRNA and CDR3a and CDR3b
sequences of each transgenic cell line were determined by next-gen sequencing. Asterisk denotes the CDR3 length of the transgenic reads: CDR3a of 48 nucleotides
encoding CAASTSGGTSYGKLTF and CDR3b of 39 nucleotides encoding CASSLGSSYEQYF. Arrow points at the CDR3 length of spiked Jurkat CDR reads: CDR3a of 51 nucleo-
tides encoding CAVSDLEPNSSASKIIF and CDR3b of 48 nucleotides encoding CASSFSTCSANYGYTF).
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induce membrane CD3 expression, indicating that no
endogenous TCRb chains were expressed. About 0.9–1.2%
of the cells expressed CD3 upon transgenic TCRb introduc-
tion, indicating, as previously reported, that low levels of
early TCRa rearrangements may occur during the DP dif-
ferentiation stage.27
Finally, we studied endogenous rearrangements by high-
throughput sequencing of PCR-ampliﬁed complementary
determining region (CDR3) RNA. Whereas CAR:28z trans-
genic PBMC derived cell line showed a normal distribution of
in frame CDR3 lengths, the HPC-derived ARC cell lines show
virtually no endogenous TCRb rearrangements and severely
reduced TCRa rearrangements (Fig. 4C). These data show that
expression of a CAR, similar to a TCRab, suppresses endoge-
nous rearrangements to a large degree leading to single receptor
ARC CD3/TCR¡ cells.
CD34C HPC-derived transgenic ARC T cells display speciﬁc
antitumor activity
We analyzed whether the in vitro generated ARC CD8C and
double DN T cells displayed the characteristic functional capac-
ities of T cells, i.e., cytokine release and speciﬁc cytotoxicity
towards cognate target cells. The in vitro generated mature T
cells were expanded for one cycle on feeder cells in the presence
of IL-7 and IL-15 and subsequently assessed for speciﬁc activ-
ity. To exclude the effects of the few CD3C cells present in these
cultures, cells were sorted for GFPCCD3¡ cells. Speciﬁc killing
by the CARC T cells was tested using the CEA¡ Colo320 and
the CEAC LS174T tumor cell lines as targets. As shown in
Fig. 5A, in vitro generated T-cell lines transgenic for CAR:z
and CAR:28z constructs killed the CEAC tumor cells speciﬁ-
cally to a similar degree. Killing was speciﬁc and largely medi-
ated by the CAR since CEAC tumor cell lines cells were killed
much more efﬁciently than CEA¡ tumor cell lines (Fig. S2).
To compare killing activity to peripheral blood derived T
cells, killing by the CAR:28z transgenic in vitro generated T
cells was assessed side by side with CAR:28z transgenic sorted
CD4C and CD8C T cells. Fig. 5B shows that whereas peripheral
blood derived CD4C T cells kill tumor cells only marginally,
peripheral blood derived CD8C T cells and in vitro generated T
cells vigorously kill CEAC LST174T cells, indicating that the in
vitro generated CD8C and DN T cells have similar cytotoxic
activity as have conventional CD8C T cells. Finally, we com-
pared killing by wtTCR-transgenic, single ARC T cells to TCR:z
and TCR:28z transgenic, single ARC T cells: again killing activ-
ity was similar, independent of the nature of the TCR that was
expressed, on T2 targets loaded with the gp100 peptide as well
as on the gp100 expressing tumor cells (Figs. 5C and S3).
To test for cytokine production, the cells were stimulated
and subsequently analyzed for intracellular IFNg, TNFa and
IL-2 production by ﬂow cytometry. We tested for IFNg and
TNFa, cytokines that are produced by NK cells as well as
CD4C and CD8C T cells and for IL-2, a cytokine produced at
high levels by peripheral blood CD4C T cells, to a lesser extent
by peripheral blood CD8C T cells and not at all by NK cells.
Maximal stimulation with PMA and ionomycin of the CAR-
transgenic T cells demonstrated that virtually all cells of both
T-cell lines were able to secrete simultaneously all three
cytokines (Fig. 5D). When stimulated by plate bound anti-IgG1
antibody, CAR:z-transgenic cells produced consistently lower
levels of cytokines and a consistently lower fraction of cells co-
produced two cytokines (8.7 and 5.6% vs 32.8% and 25.7%)
compared to CAR:28z-transgenic cells, which is in line with the
previous reports.5 Speciﬁc cytokine production was assessed
after stimulation with the CEA¡ Colo320 and the CEAC
LS174T tumor cells. Although there was some background
IFNg secretion that is AR-independent by 5–10% of the cells,
upon speciﬁc CAR engagement, T cells secreting all three cyto-
kines are observed only after stimulation with the CEAC cell
line LST174T cells. This is especially the case for the CAR:28z-
transgenic cells.
Finally, we compared speciﬁc cytokines secretion by in vitro
generated wtTCR transgenic T cells with TCR:z and TCR:28z-
transgenic T cells (Fig. 5E). After speciﬁc gp100 peptide addi-
tion to T2 HLA-A2C antigen presenting cells, the levels of all
three cytokines were increased. Similar to the CAR transgenic
cells, the TCR:28z transgenic T cells with built-in CD28 co-
stimulatory domain demonstrated higher numbers of cells that
produced two cytokines compared to wt or TCR:z transgenic
cells (13.2% and 30.8% for TCR:28z vs 1.7% and 7.0% for
wtTCR and 4.7% and 15.0% for TCR:z). This was the case
upon stimulation with T2-gp100 peptide as well as upon co-
incubation with gp100C cell lines FM3. In conclusion, in vitro
CD34C derived T cells, in particular when transgenic for an AR
with build-in CD28 co-stimulatory domain, are highly cyto-
toxic and cytokine producing cells despite their CD8C or DN
phenotype. These cells are CD3 negative, mono-speciﬁc T cells
that produce high levels of IL-2 and IFNg upon speciﬁc stimu-
lation discriminating these cells from NK cells.
Discussion
We demonstrated that CAR or TCR expressing T cells can be
generated from cord blood HPCs in vitro. Importantly, CARs
as well as TCRs block the endogenous rearrangements of the
TCRa and TCRb locus resulting in mono-speciﬁc T cells since
they express only the transgenic AR and lack the endogenous
TCR. In addition, we showed that these T cells are very potent
in cytokine production as well as cytotoxicity especially when
CAR or TCR-constructs are linked to the CD28 co-stimulation
signal. Importantly, the CD28 co-stimulation signal does not
compromise T-lineage differentiation and the development of
functional T cells from HPC.
By transducing CD34C HPCs, which we subsequently
differentiated upon OP9-DL1 feeder cells, we took advan-
tage of the phenomenon of allelic exclusion to generate
mono-speciﬁc, transgenic ARC T-cell populations that do
not express a polyclonal, endogenous TCR repertoire as is
the case with transgenic peripheral blood T cells. It has
been shown in TCR-transgenic mice, that rearrangement at
the TCRb locus are completely blocked, whereas the TCRa
rearrangements are reduced.30 TCRa rearrangements are
operative during the DP stage in the thymus and are termi-
nated by positive selection. In humans, TCRb locus rear-
rangements are suppressed in TCR-transduced HPCs which
were transplanted in humanized mice, as well as in T cell
derived from iPSC generated from a T-cell clone.31-34 We
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have shown that also in OP9-DL1 cultures TCRb rearrange-
ments are blocked and that TCRa rearrangements can be
largely prevented by early agonist selection, thereby reduc-
ing the length of the DP stage.27 Since TCR:28z-transgenic
cells already mature spontaneously, it is not surprising that
these cells rapidly pass through the DP stage and that
TCRa rearrangements are severely reduced. As shown in
this report, also CARs potently block TCR locus rearrange-
ments to the extent that virtually no TCR/CD3 expressing
cells are generated. The observation is in line with a previ-
ous report that CAR-transgenic iPSC-derived T cells have a
reduced TCR repertoire, however these iPSC cells were
Figure 5. Antitumor activity of CD34C HPC-derived transgenic ARC T cells. Functional analysis of the in vitro generated ARC cells after one round of expansion on feeder
cells. (A) Killing activity at different E:T ratios against the CEA¡ COLO320 and the CEAC LST174T tumor cell line. HPC-derived cells were sorted for GFPCCD3¡ cells before
expansion on feeder cells. Error bars represent SD of duplicate determinations (N D 3). (B) Killing activity of CAR:28z transgenic peripheral blood CD4C and CD8C (PB-
derived) and in vitro generated, CD34C HPC-derived CAR:28z transgenic cells. Error bars represent SD of duplicate determinations (N D 2). (C) Killing activity of wtTCR,
TCR:z and TCR:28z transgenic in vitro generated cells toward gp-100C FM3 and gp100¡ COLO320 tumor cell lines. TCR:z and TCR:28z transgenic cultures were sorted for
Vb14CCD3¡, wtTCR transgenic cultures were sorted for Vb14CCD3C cells. Error bars represent SD of duplicate determinations (N D 5). (D) Cytokine production by CAR:z
and CAR:28z transgenic T-cell lines, either unstimulated or stimulated by PMA and ionomycin, plate-bound anti-IgG1, CEA¡ COLO320 or CEAC LST174T cells. All dot plots
were gated on GFPC cells (N >3 for all conditions). (E) Cytokine production by wtTCR, TCR:z and TCR:28z transgenic T-cell lines, sorted for Vb14C cells, after addition of
T2 cells pre-incubated with an inﬂuenza peptide (T2-INF) or a gp100 peptide (T2-gp100), gp100¡ COLO320 or gp100C FM3 tumor cell lines (N >3 for all conditions).
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derived from a T-cell clone.35 As the T-cell clone has rear-
ranged TCRb and TCRa locus, it is not unexpected that de
novo rearrangements were inhibited and the issue whether
this was caused by the CAR or by the pre-TCR was not
addressed. A report by Zakrzewski et al. using transfer of
murine CD19-CAR-transgenic T-cell precursors in mice
reported no effect of the ﬁrst generation CAR on the devel-
opment of the TCRb repertoire, nor on the expression of
CD4C, CD8C and CD3.36 However, in a recent study, HIV-
speciﬁc CAR-transduced human HPCs injected in BLT
mice resulted in a reduced number of CD3 positive cells in
the thymus and the TRECs per cell were decreased, indicat-
ing that TCR rearrangements were blocked.37 The latter
data in concert with the data presented here strongly sug-
gest that also CARs block rearrangements during T-cell
development in vivo as well as in vitro with the result that
mono-speciﬁc T cells are generated. Discrepant results
could be explained by the expression level of the CAR in
the thymus as we have shown that low expression affects T-
cell differentiation to a lesser degree. As expression of cer-
tain promoters such as CMV promoters are shut down in
the thymus this may explain the discrepant results in the in
vivo studies.
Alternative methods to generate mono-speciﬁc T cells with-
out expression of the endogenous TCR, using gene editing of
peripheral blood T cells, have limitations. Gene editing meth-
ods can be applied to CAR T cells as one TCR-chain can be
edited and by subsequent screening for CD3¡ CARC cells,
CD3/TCR negative CAR T cells can be isolated also from
peripheral blood. However, for TCR transgenic T cells, this
method is more cumbersome, as both chains have to be elimi-
nated to prevent cross-pairing. In addition, this requires
lengthy screening, which may not be practical in a clinical set-
ting.15 Furthermore, gene editing has its own pitfalls, in partic-
ular off-target mutations which may prove to be oncogenic
depending on the targeted sequence involved.
The absence of endogenous TCRs has several advantages for
adoptive cell therapy. Interference with expression of the
tumor-speciﬁc TCR is minimized due to the expected absence
of cross-pairing. Cross-pairing may induce unexpected autor-
eactivity and GvHD as well as reduce the expression levels of
the transgenic TCR.13,16 In the approach described here, addi-
tional measures were taken to prevent interference with the
tumor-speciﬁc TCR expression: The linked CD3z and CD28
signaling sequences force both transgenic chains to preferen-
tially pair with each other and not with endogenous chains.17,20
In addition, as these TCRs are surface-expressed independent
of CD3, there is no competition for endogenous CD3 as the
cytoplasm brightly stains for superﬂuous CD3 that cannot
incorporate into the membrane due to lack of a TCR.
The CD28 co-stimulatory signal may not only prevent the
development of anergy, but may also signiﬁcantly increase sur-
vival and proliferation of these cells upon antigen stimulation.17
Here, we show that the mature CD27CCD1a¡ cells survive and/
or proliferate much better in the OP9-DL1 cultures compared
to ARC cells without co-stimulatory signal and we show that
these cells produce higher levels of cytokines including IL-2.
The high levels of cytotoxic activity together with polycytokine
secreting capabilities, despite their DN or CD8C phenotype,
make these cells good candidates for a redirected cell therapy of
cancer.
A limitation of this study is the lack of proof of in vivo func-
tionality. Preliminary in vivo data suggest that these cells
require human IL-15 for survival and experiments with human
IL-15 transgenic mice are now being set up.
Two groups reported rejuvenation of T cells by generating
iPSCs from T-cell clones and subsequent differentiation to T
cells.33,34,38 These authors report that they obtain CD62LC
CD45RAC T cells and that these T cells may have again
become naive, conventional T cells. As the cells they describe
are in many respects similar to the T cells derived here from
HPCs, data underline their potential value in cell therapy.
The mono-speciﬁc ARC T cells can be applied in several
ways in cancer therapy. Similar to allogeneic virus-speciﬁc T
cells that are administered to patients after bone marrow trans-
plantation, one can generate a bank of common HLA-express-
ing, cord blood HPC-derived allogeneic CAR T cells. In this
way, partially matched CAR T cells can be administered to
post-transplant patient. Using this approach, CMV-speciﬁc T
cells induce remission of CMV disease.39 Whether such an
approach would also work for CAR T cells in treatment of
malignancies is unclear, as it has been shown that survival of
CAR T cells for at least 6 mo is required for cure.3 Alternatively,
allogeneic CAR therapy could be combined with heavy immu-
nosuppressive conditioning. This conditioning will work in
synergy with CAR T cells on the tumor and at the same time
will prevent anti-CAR T cell alloresponses and anti-CAR
responses, thus allowing the cells to survive longer. In the most
intensive therapy, the latter could be combined with T-cell
depleted stem cell therapy, either using HLA matched cord
blood or adult mobilized blood cells. In these cases, stem cell
chimerism will induce lifelong tolerance sustaining survival of
the donor CAR T cells. In all these instances, CAR T cells can
be generated from healthy donor material, under optimal con-
ditions and sufﬁciently in numbers in advance for a broad
cohort of patients.
Materials and methods
Isolation of human cells
Postnatal thymus (0–12 y of age) and cord blood were obtained
and used following guidelines of the Medical Ethical Commit-
tee of the Ghent University Hospital (Belgium). Informed con-
sent was obtained in accordance with the Declaration of
Helsinki (Ethics Committee UZ Ghent decision
B670201215078). Human T-lineage committed CD34C cells
were isolated from postnatal thymus and CD34C HPCs were
isolated from cord blood by magnetic activated cell separation
(MACS, Miltenyi, cat# 130-046-703). Cord blood CD34C cells
were subsequently T-lineage committed by culture on OP9-
DL1 in the presence of 50 ng/mL SCF, 20 ng/mL Flt3L and 10
ng/mL IL7 for 12–14 d. Purities were usually > 90%.
LST174T (ATCC CCL 188) and H508 (ATCC CCL 253) are
CEA-expressing carcinoma cell lines, Colo320 (ATCC CCL
220), Colo201 (ATCC CCL 224) and H716 (ATCC CCL251)
are CEA¡ colon carcinoma cell lines, FM3, MEL624 and
MEL526 are HLA-A2C melanoma cell lines expressing gp100
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obtained from R Debets. JY is a human HLA-A2C B cell line
and Jurkat is a CD3C leukemic line. These cell lines were main-
tained under standard culture conditions.
Production of retroviral vectors
The different construct used are represented in Fig. S1. The car-
cino-embryonic antigen (CEA)-speciﬁc CAR:z and CAR:28z
constructs5,40 were transferred into the LZRS IRES eGFP (LIE)
vector using XhoI and BglII and viral particles were produced
using the Phoenix packaging cell line. Retroviral supernatans
were collected at day 14 after transfection and hygromycin
selection and frozen until use. Transduced cells were detected
either by eGFP expression or by an anti-IgG antibody directed
against the human IgG1 spacer domain present in the extracel-
lular domain of both CARs.
The TCR constructs were generated from a gp100-speciﬁc
(epitope: YLEPGPVTA) HLA-A2 restricted receptor using
TRBV14s1.16,17,41 The TCR:z was constructed by linking the
extracellular part of both the wt TCRa and TCRb chain to the
full length transmembrane and intracellular parts of CD3z.16,42
The TCR:28z was constructed by linking the extracellular part
of both the wt TCRa and TCRb chain to the CD28-CD3z tail
described above (kindly provided by H. Abken, Cologne,
Germany) (Fig. S1).20 wtTCR, the TCR:z and the TCR:28z
cDNAs were cloned into pBullet retroviral vectors. VSV-G
envelope-pseudotyped Moloney murine leukemia virus retrovi-
ral particles that contain TCR RNAs were freshly produced by
a co-culture of the packaging cells 293T and Phoenix-A follow-
ing calcium phosphate transfections and were used fresh.
wtTCR, the TCR:z and the TCR:28z were detected by a Vb14-
speciﬁc antibody (Beckman Coulter, cat# PN IM2047).
Retroviral transduction
Fresh thymic CD34C were pre-activated for 1 d in the presence
of cytokines (5 ng/mL SCF and 10 ng/mL IL7). CD34C CB cells
were transduced after T-lineage committment (see above) in
the presence of SCF (5 ng/mL, PeproTech, 300–07)), Flt-3L
(10 ng/mL, PeproTech 300–19) and IL-7 (10 ng/mL, R&D Sys-
tems, 207-IL). Transduction efﬁciencies varied but were usually
between 20% and 60% for the CAR-transgenic cells, and
between 2% and 8% for the TCR transgenic cells. Unless stated
otherwise, the mixture of transduced and untransduced cells
was cultured without prior Fluorescent Activated Cell Sorting
(FACS) on OP9-DL1 cells.
OP9-DL1 co-cultures
Transduced cells were co-cultured on a subconﬂuent OP9-DL1
cell layer in a-MEM medium (Gibco, 22561–021) supple-
mented with 20% FBS (Bovogen, SFBS), 2 mM L-glutamine,
100 IU/mL penicillin, 100 IU/mL streptomycin, 5 ng/mL SCF,
10 ng/mL Flt3L and 10 ng/mL Il-7, as described previously.43
Agonist peptide stimulation
Cells were harvested from OP9-DL1 and were, either as such or
after FACS sorting for immature DP cells, seeded in tissue
culture plates (BD Biosciences) in complete IMDM in the pres-
ence of 10 ng/mL IL-7 for 7 d. The gp100 YLEPGPVTA peptide
and, as irrelevant control, inﬂuenza matrix protein M158–66
peptide were used (Anaspec by Eurogentec). For the CAR
experiment, a CEA-expressing adherent cell line (LST174T)
was added to the cultures.
T-cell expansion
Cultures containing mature CD27CCD1a¡ cells were expanded
on irradiated allogenic feeder cells, consisting of a mixture of
40-Gy irradiated peripheral blood mononuclear cells and 50-
Gy irradiated JY cells. Cells were cultured in IMDM (Gibco)
with 10% FBS, supplemented with 2 mg/mL PHA (Oxoid,
R30852801) or 10 ng of IL-7 and IL-15 (R&D Systems
247-ILB-025).
Flow cytometry and antibodies
Surface marker staining was performed in DPBS with 1% FBS
using antibody concentration recommended by the supplier.
Intracellular staining was performed following the supplier’s
protocol using Fix & Perm (BD Biosciences). Flow cytometric
analysis was performed on the LSR II and cell sorting on the
ARIA II (both BD Biosciences), both equipped with fur lasers.
All populations studied were devoid of dead cells based on pro-
pidium iodide negativity and of doublets based on FSC-A FSC-
W ratios. The following anti-human monoclonal antibodies are
CD5 (BD Biosciences, cat# 345782), IgG-Fc (eBioscience, cat#
12-4998-82), Vb14 (Beckman Coulter, cat# PN IM2047); APC-
conjugated: CD8a (BD Biosciences, cat# 345775), TCRab (Mil-
tenyi, cat# 130-091-237), CD45 (Miltenyi, cat# 130-091-230),
CD34 (BD Biosciences, cat# 345804); Amcyan-conjugated:
CD45 (BD Biosciences, cat# 339192); V450-conjugated: CD7
(BD Biosciences, cat# 642916), CD3 (eBioscience, cat# 48-
0038-42); APC-Cy7-conjugated: CD27 (eBioscience, cat#
47-0279-42); PE-Cy7-conjugated: CD8b (eBioscience, cat# 25-
5273-42); AF-700-conjugated: CD4C (BD Biosciences, cat#
557922); BV510-conjugated: CD45 (BD Biosciences, cat#
563204); biotin-conjugated: CD1a (ATCC); PerCPCy5.5-conju-
gated: Streptavidin (eBioscience, cat# 45-4317-82).
Flowcytometric determination of cytokine production
One hundred thousand culture expanded cells were stimulated
by co-incubation with a cell line expressing the relevant antigen
(LS174T, FM3 or Colo320) at 105 cells in 96-well ﬂat-bottom
plates. After 1 h, GolgiSTOP (BD Biosciences, cat#
51-2092KZ)) was added. After an additional 16 h of stimula-
tion, the cells were harvested, permeabilized, labeled and ana-
lyzed for cytokine expression using TNF-PE-Cy7 (BD
Biosciences, cat#557647), IFNg-PE (BD Biosciences, cat#
340452) and IL2-APC (BD Biosciences, cat# 554567).
51Chromium release assay
Target cells were labeled with51 Chromium, washed and used at
different effector to target ratios. T2 cells were loaded for 2 h
with the indicated peptide at a concentration of 10 mg/mL
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unless otherwise indicated before radioactive labeling. Effector
cells consisted of culture expanded peripheral blood mononu-
clear cells or OP9-DL1 cultures. After a 4 h of co-incubation,
supernatant was harvested and measured in a 1450 LSC &
Luminescence Counter (Perkin Elmer). Speciﬁc lysis is calcu-
lated as followed: (experimental release ¡ spontaneous
release)/(maximal release ¡ spontaneous release) £ 100%.
Real-time quantitative PCR (RT-qPCR)
Total RNA was prepared using the miRNeasy minikit (Qiagen).
cDNA synthesis was performed by the Superscript First Strand
Synthesis System for RT-PCR kit (Invitrogen). RT-qPCR with
the SYBR Green I technology was performed using the Light-
Cycler 480 SYBR Green I Master kit on a LightCycler 480 II
(both Roche) according to the manufacturer’s protocol. Used
primers (Biolegio, Nijmegen, Netherlands) are listed in
Table S1. Results were analyzed using the ddCt method using
actin as a reference gene.
CDR3a and CDR3b high-throughput sequencing
RNA was isolated from culture expanded HPC-derived
wtTCR, TCR:z, TCR:28z, CAR:z, CAR:28z transgenic cell
lines and from a PBMC-derived CAR:28z transgenic T cell
line (105–106 cells) with the RNeasy microkit (Qiagen) fol-
lowed by template-switch anchored RT-PCR.44 To each sam-
ple, Jurkat RNA was added for a total of 10% of the amount
of RNA as an internal standard. A template-switch adaptor,
AAGCAGTGGTATCAACGCAGAGTACATrGr GrG, was
ligated at the 50 end of mRNA during cDNA generation using
the Superscript II RT enzyme (Invitrogen). The cDNA prod-
uct was puriﬁed using AMPure XP Beads (Agencourt). Then,
PCR ampliﬁcation (Lightcycler, Roche) was performed using
a Ca speciﬁc primer (50-GTCTCGTGGGCTCGGAGATGTG-
TATAAGAGACAG TCTCAGCT GGTACACGGCAGGGT-
CAGGGT-30, adapter in italic) or a Cb speciﬁc primer (50-
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG TGCT
TCTGATGGCTCAAACACAGCGACCT-30, adapter in italic)
containing an adapter used in subsequent sequencing, and a
primer complementary to the template-switch adapter (50-
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG AAG-
CAGTGGTATCAACGCAG-30, adapter in italic) with the
KAPA Real-Time Library Ampliﬁcation Kit (Kapa Biosys-
tems). After puriﬁcation with AMPure XP Beads, an index
PCR with Illumina sequencing adapters was performed using
the Nextera XT Index Kit. This second PCR product was
again puriﬁed with AMPure XP beads. High-throughput
sequencing of the generated amplicon products containing
the CDR3a or CDR3b sequences was performed on an Illu-
mina MiSeq platform using the V2 300 kit, with 200 bp at
the 30 end (read 2) and 100 bp at the 50 end (read 1) (at the
GIGA center, University of Liege, Belgium). CDR3 sequences
were obtained by aligning the fastq ﬁles (read 2) with the
MiXCR software version 1.7.145 with speciﬁed “-loci” param-
eter “TRA” and “TRB” for the alignment of CDR3a and
CDR3b, respectively. Then, CDR3 sequences were assembled
and exported. Spectratyping plots were generated via the rou-
tine PlotFancySpectratype of VDJTools version 1.0.7.46
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